Serum exosomal long noncoding RNAs Inc-FAM72D-3 and Inc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma

Zhicheng Yao1,*, Changchang Jia2,*, Yan Tai3, Hao Liang1, Zhaozhong Zhong4, Zhiyong Xiong1, Meihai Deng4, Qi Zhang2

1Department of General Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
2Department of Cell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
3Department of Liver Disease Lab, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
4Department of Hepatobilliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
*Co-first author and Equal contribution

Correspondence to: Qi Zhang; email: kee.kee@126.com
Keywords: hepatocellular carcinoma, exosomes, IncRNAs, Inc-FAM72D-3, Inc-EPC1-4
Received: October 22, 2019 Accepted: May 1, 2020 Published: June 18, 2020

Copyright: Yao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Long noncoding RNAs (IncRNAs), such as LINC00462, HOTAIR, and MALAT1, are significantly upregulated in hepatocellular carcinoma (HCC) tissues. However, IncRNA expression in the serum of HCC patients is still unclear. To identify candidate IncRNAs for HCC diagnosis, we purified exosomal total RNA from the serum of healthy volunteers (controls) and hepatitis, cirrhosis, and HCC patients. To assess the function of IncRNAs, small interfering RNAs and overexpression vectors were designed and cell viability and cell apoptosis assays conducted. The exosomes of the control group had a larger number of IncRNAs with a high amount of alternative splicing compared to hepatic disease patients. qPCR assays showed that Inc-FAM72D-3, Inc-GPR89B-15, IncZEB2-19, and Inc-EPC1-4 are differentially expressed in HCC. Furthermore, the expression level of Inc-EPC1-4 correlated with age. While the expression levels of Inc-GPR89B-15 and Inc-EPC1-4 correlated with serum alpha-fetoprotein level. Inc-FAM72D-3 knockdown decreased cell viability and promoted cell apoptosis, indicating that Inc-FAM72D-3 functions as an oncogene in HCC. In contrast, Inc-EPC1-4 overexpression inhibited cell proliferation and induced cell apoptosis, indicating that it functions as a tumor suppressor gene. Collectively, these findings show that Inc-FAM72D-3 and Inc-EPC1-4 play a novel role that might contribute to hepatocarcinogenesis and identify potential candidate biomarkers for HCC diagnosis.

INTRODUCTION

Liver cancer, also called hepatocellular carcinoma (HCC), is the fifth-most common cancer worldwide, with a mortality rate that increased by almost 3% per year from 2010 to 2014 [1, 2]. Surgical treatment of HCC might be effective in the initial stage of the disease. However, most HCC patients present with intra- and extrahepatic metastasis upon diagnosis, which limits their treatment options to radiotherapy and chemotherapy. Unfortunately, the treatment efficacy of radiotherapy and chemotherapy is limited [3]. Therefore, early diagnosis of HCC is of utmost importance. Currently, the most commonly used methods of diagnosing HCC involve imaging or detection of tumor biomarkers, such as alpha-fetoprotein (AFP), from the patient’s serum. However, these techniques are less
sensitive for early diagnosis of HCC [4]. Therefore, it is important to identify novel diagnostic and prognostic molecular markers to improve early diagnosis of HCC.

Long noncoding RNAs (lncRNAs) are non-protein-coding transcripts with a length of >200 nucleotides. lncRNAs participate in various biological processes, such as tumorigenesis, metastasis, and proliferation [5–8], so they are considered diagnostic biomarkers for multiple cancers, such as gastric, bladder, colorectum, prostate, and renal cancers [9–12]. lncRNAs, such as LINC00462, HOTAIR, MALAT1, CCAT1, CCAT2, LINC00161, and SPRY4-IT1, are significantly upregulated in HCC tissues [13–19]. However, lncRNA expression in the serum of HCC patients is still unclear.

Circulating exosomes are small 30–150 nm membrane vesicles that are released into extracellular environments, such as serum or plasma [20]. They usually contain proteins and RNAs that perform various functions, such as cell–cell communication and signaling. Researchers have focused on identifying biomarkers in blood exosomes as a minimally invasive sample source that reflects the signatures of pathological conditions such as cancer and atherosclerosis without the need for surgical sample collection [21]. Although various microRNAs (miRNAs) and proteins are found inside exosomes, indicating that they could potentially be used as diagnostic biomarkers for HCC, little is known about the serum exosomal lncRNAs in HCC [22–24].

This study determined whether exosomal lncRNAs have functions in hepatic diseases and could potentially be used as diagnostic biomarkers. We purified exosomal lncRNAs from 45 healthy volunteers, 45 hepatitis patients, 45 cirrhosis patients, and 45 HCC patients. We conducted RNA sequencing (RNA-seq) to obtain expression profiles and performed correlative and functional analyses of candidate lncRNAs.

**RESULTS**

**Exosome particle and protein concentrations modified in hepatic diseases**

To investigate exosomal lncRNAs involved in hepatic diseases, we collected serum from healthy volunteers and hepatitis, cirrhosis, and HCC patients. Exosomes were purified by ultracentrifugation, and their sizes were determined by NTA. As shown in Supplementary Figure 1A, particle diameters of exosomes ranged from ~50 to 150 nm for the four groups, and there was no significant difference in the size distribution. CD63, TSG101, and CD9, which are surface antigens commonly expressed in exosomes, were detected in all four groups (Supplementary Figure 1B). In contrast, calnexin protein expression was not detected in any group (Supplementary Figure 1B). These findings indicated successful purification of exosomes and also that they were of uniform size across the four groups.

To further evaluate potential differences between exosomes of healthy volunteers and hepatic disease patients, we measured the particle and protein concentrations of exosomes. The control and hepatitis groups had similar particle concentrations, but the particle concentration was 50% lower for the cirrhosis group and 20% higher for the HCC group (Table 1). The hepatitis, cirrhosis, and HCC groups also had higher protein concentrations compared to the control group, indicating that hepatic diseases induce changes in both particle concentration and protein concentration of exosomes.

**Bioinformatics study of exosomal lncRNAs**

To further qualify differences between the exosomes of healthy volunteers and hepatic disease patients, we purified exosomal total RNA and conducted RNA-sequencing. RNAs were annotated, and lncRNAs were extracted from the data for further analysis. For all four groups, lncRNAs were mostly intronic. In the control group, we determined 946 relevant genes to be involved in lncRNA formation, with 1955 associated alternative splicing events (Figure 1A). In contrast, exosomes of the hepatitis, cirrhosis, and HCC groups had obviously fewer lncRNAs with fewer alternative splice events (ranging from 4- to 40-fold reduction), indicating that liver disease downregulates lncRNA production and alternative splicing of lncRNAs. However, exosomes of all four groups had similar length distributions for lncRNAs, the majority of which were ~500 nt (Figure 1B). The heatmap showed that compared to the control group, 34,175 lncRNAs were upregulated and 15,553 downregulated in the hepatitis group, 16,673 lncRNAs were upregulated and 22,033 downregulated in the cirrhosis group, and 28,475 lncRNAs were upregulated and 16,453 downregulated in HCC group (Figure 1C and Supplementary Tables 2–4). We also examined chromosome distributions of lncRNAs. In the hepatitis, cirrhosis, and HCC groups, upregulated lncRNAs were most abundant on chromosomes 1 and 2, being about twice as much as downregulated lncRNAs. Interestingly, in the cirrhosis group, upregulated lncRNAs were also enriched on chromosomes 5 and 6 and were six times more than downregulated lncRNAs (Figure 1D), indicating that lncRNAs that play a role in liver disease are more distributed on chromosomes 1 and 2.

To determine the potential relevance of differentially expressed lncRNAs from the hepatitis, cirrhosis, and HCC groups, we conducted KEGG and GO analysis. In KEGG pathway annotation, the pathways were mainly
RNA transport and protein processing in the endoplasmic reticulum (Figure 2A): Ras, Rap1, and phosphatidylinositol-3 kinase/protein kinase B (PI3K/Akt) signaling pathways, which were enriched in the control group compared to hepatitis and HCC groups (Figure 2C, 2E). In addition, GO analysis showed that significantly expressed lncRNAs are more focused on the “cell” and “cell part” of cellular components, the “binding” of molecular function, and the “cellular process” and “biology regulation” of biological process in the control group compared to hepatitis and HCC groups (Figure 2B, 2D, 2F), indicating that pathways in KEGG analysis and biological processes in GO analysis play important roles in the occurrence and development of liver diseases. Regulatory networks of common significantly differentially expressed lncRNAs revealed many clusters with low interconnectedness between the genes (Figure 3), indicating that the underlying mechanism is complicated and that each lncRNA might perform distinct functions in regulating specific genes.

Validation of the expression of differentially expressed lncRNAs

To further investigate the expression differences in exosomal lncRNAs of the four groups, we performed qPCR and examined the expression levels of nine lncRNAs. The expression levels of Inc-GPR89B-15 and Inc-ZEB2-19 verified by qPCR were consistent with RNA-seq results in hepatitis, cirrhosis, and HCC groups (Figure 4). Inc-FAM72D-3 expression in hepatitis, cirrhosis, and HCC groups was significantly high compared to the control group, while Inc-EPC1-4 expression in hepatitis, cirrhosis, and HCC groups was significantly low compared to the control group (Figure 4). Four lncRNAs (Inc-GPR89B-15, Inc-FAM72D-3, IncEPC1-4, and Inc-ZEB2-19) with differential expression in the HCC groups were selected for further evaluation.

Next, to determine the relationship between exosomal expression and diseases, we compared the expression levels of these lncRNAs between the control group and hepatitis, cirrhosis, and HCC groups (Table 2). As indicated by the area under the curve (AUC) of the receiver operating characteristic (ROC) curves, each of the four IncRNAs showed a close correlation with hepatic diseases (Figure 5). Of them, Inc-ZEB2-19 had the highest AUC in all three comparisons, indicating a significant correlation between Inc-ZEB2-19 exosomal expression and hepatic diseases. Since most IncRNA expression levels were correlated with hepatitis, cirrhosis, and HCC to some extent, we combined the data from the patients and calculated the overall correlation between different patient characteristics and lncRNA expression (Table 3). The results suggested that the expression of Inc-EPC1-4 was significantly correlated with age, while the expression of Inc-GPR89B-15 and Inc-EPC1-4 was significantly correlated with AFP concentration (P < 0.05).

Function analysis of differentially expressed lncRNAs

The expression levels of Inc-GPR89B-15, Inc-FAM72D-3, IncEPC1-4, and Inc-ZEB2-19 were detected in different cell lines using qPCR (Supplementary Figure 2). Inc-FAM72D-3 and Inc-EPC1-4 expression was significantly different in different cell lines (Supplementary Figure 2). Therefore, we generated siRNAs and overexpression vectors to inhibit and promote Inc-FAM72D-3 and Inc-EPC1-4 expression. On the basis of their high expression levels, we selected HepG2 and SNU-423 cells for evaluation by siRNA-mediated knockdown, while on the basis of their low expression levels, we selected MHCC-LM3 and MHCC97-H cells for vector-mediated overexpression. The Inc-FAM72D-3 siRNA-1 significantly downregulated Inc-FAM72D-3 expression in HepG2 cells with a small but significant decrease in SNU-423 cells, while all three Inc-EPC1-4 siRNAs downregulated Inc-EPC1-4 expression (Supplementary Figure 3, left). Therefore, we selected Inc-FAM72D-3 siRNA-1 and Inc-EPC1-4 siRNA-1 for subsequent analysis (Supplementary Figure 3, right). qPCR results also confirmed that MHCC-LM3 and MHCC97-H overexpression was successful (>150-fold increase).

Table 1. Comparison of serum exosome particle concentrations and protein concentrations in healthy volunteers and patients with hepatic diseases.

| Exosome grouping   | Particle concentration (particles/ml) | Exosome protein concentration (μg/μl) |
|-------------------|-------------------------------------|-------------------------------------|
| Normal            | 3.40E+11                            | 9.127                               |
| Hepatitis         | 3.81E+11                            | 11.345 *                            |
| Cirrhosis         | 1.97E+11 *                          | 11.399 *                            |
| Hepatocellular carcinoma | 4.54E+11 *                          | 11.290 *                            |

Compared with the control group, * p < 0.05 was considered to be significantly different.
Figure 1. Bioinformatic analyses of lncRNAs. (A) Number of genes (red) and alternate splicing events (green) for lncRNAs from control, hepatitis, cirrhosis, and HCC groups. (B) Length distribution of lncRNAs in control, hepatitis, cirrhosis, and HCC groups. (C) Cluster heatmaps of lncRNA expression profiles in the control group compared to hepatitis, cirrhosis, and HCC groups. Gradient green represents downregulated lncRNAs, while gradient red represents upregulated lncRNAs. (D) Chromosomal distributions of lncRNAs in the control group compared to hepatitis, cirrhosis, and HCC groups. IncRNA, long noncoding RNA; HCC, hepatocellular carcinoma.
Figure 2. Functional analyses of significantly expressed lncRNAs. (A, C, E) KEGG pathway enrichment of the differentially expressed lncRNAs in control, hepatitis, and HCC groups. (B, D, F) GO analysis of differentially expressed lncRNAs in control, hepatitis, and HCC groups, respectively. lncRNA, long noncoding RNA; HCC, hepatocellular carcinoma.
Next, we identified candidate miRNAs predicted bioinformatically to be targeted by these IncRNAs. qPCR results confirmed that hsa-miR-5787 is targeted by Inc-FAM72D (Figure 6A). hsa-miR-29b-1-5p, hsa-miR-19b-1-5p, hsa-miR-511-5p, and SLCO1B1 levels were each significantly downregulated by Inc-EPC1-4 siRNA-1, while CCND1 levels were slightly upregulated (Figure 6B–6D). These results indicated that hsa-miR-5787 might be a target of Inc-FAM72D-3, while Inc-EPC1-4 might target several genes, including hsa-miR-29b-1-5p, hsa-miR-511-5p, and SLCO1B1.

Figure 3. Regulation network of differentially expressed IncRNAs. IncRNA, long noncoding RNA.
To further assess the functional effects of Inc-FAM72D-3 expression modulation, we performed cell proliferation and apoptosis assays. HepG2 cells transfected with Inc-FAM72D-3 siRNA-1 or Inc-EPC1-4 siRNA-1 and MHCC-LM3 cells transfected with pcDNA3.1-FAM72D-3 or pcDNA3.1-EPC1-4 were evaluated by MTS and flow cytometry assays. When HepG2 cells were transfected with Inc-FAM72D-3 siRNA-1 for 48 h, ~50% of HepG2 cells were viable, which was low compared to the siRNA negative control (NC) group, indicating that Inc-FAM72D-3 siRNA-1 significantly inhibits HepG2 cells proliferation (Figure 7A). In addition, pcDNA3.1-FAM72D-3 enhanced HepG2 cell viability. Also, the early apoptotic percentage of HepG2 cells transfected with Inc-FAM72D-3 siRNA-1 was 9.55%, which was low compared to the siRNA NC group, indicating that Inc-FAM72D-3 siRNA-1 induces HepG2 cell apoptosis. In addition, pcDNA3.1-FAM72D-3 induced slight inhibition of cell apoptosis compared to the pcDNA3.1 group (Figure 7B). Inc-EPC1-4 siRNA and pcDNA3.1-EPC1-4 had the opposite effect: IncEPC1-4 siRNA increased cell viability and decreased apoptosis, while pcDNA3.1-EPC1-4 decreased cell viability and

Figure 4. Differentially expressed IncRNAs in exosomes of control, hepatitis, cirrhosis, and HCC groups validated by real-time qPCR. IncRNA, long noncoding RNA; HCC, hepatocellular carcinoma; qPCR, quantitative polymerase chain reaction.
increased apoptosis (Figure 7C, 7D). These results indicated that \textit{inc-FAM72D}-3 functions as an oncogene that is upregulated in HCC, while \textit{inc-EPC1}-4 functions as a tumor suppressor gene that is downregulated in HCC.

**DISCUSSION**

In this study, we examined exosomal lncRNAs that are differentially expressed in hepatic disease patients. Increased \textit{inc-FAM72D}-3 and decreased \textit{inc-EPC1}-4 levels are clearly correlated with HCC; these findings were verified by qPCR for a group of 180 healthy volunteers and hepatic disease patients. Functional validation with MTS and cell apoptosis assays showed that \textit{inc-FAM72D}-3 knockdown induces significant inhibition of cell proliferation and promotes cell apoptosis, while upregulation of \textit{inc-EPC1}-4 expression has the same effect. There are currently no reports on the exact underlying mechanism; however, we have elucidated new roles for them in HCC and other hepatic diseases. On the basis of our bioinformatic prediction of downstream targets of \textit{inc-FAM72D}-3 and \textit{inc-EPC1}-4, several candidate target genes and miRNAs have been shown to regulate cell proliferation and cell apoptosis. These included hsa-miR-511-5p, which we had demonstrated increases by pcDNA3.1-\textit{inc-EPC1}-4 transfection. Consistent with our findings, \textit{miR-511} acts as a tumor suppressor gene that attenuates tumor cell growth and proliferation by inhibiting tribbles pseudokinase 2 (TRIB2) [25]. TRIB2 is involved in the etiology of various cancers, including leukemia, melanoma, lung cancer, and HCC. In addition, \textit{miR-511} regulates the AKT signaling module, which plays a pivotal function in cell proliferation, differentiation, metabolism, and apoptosis in HCC [26–29]. \textit{MiR-29b}, which we had shown is induced by pcDNA3.1-\textit{inc-EPC1}-4 and inhibited by \textit{inc-EPC1}-4 siRNA, has also been suggested to participate in the inhibition of angiogenesis and tumorigenesis of cancer through the Akt3 signaling pathway [30]. Therefore, decreased \textit{inc-EPC1}-4 siRNA levels in HCC might enhance cell growth by activating the AKT pathway.

We also demonstrated that SLCO1B1 is targeted by \textit{inc-EPC1}-4. The sequential administration of sorafenib (front-line treatment) and regorafenib (second-line treatment) efficiently improves therapeutic efficacy in advanced HCC. Influx transporters (SLCO1B1, SLCO1B3, and SLC22A1) are highly involved in the metabolism and clearance of these chemotherapy agents in the liver, while downregulation of these influx transporters might inhibit cellular uptake, thereby discounting their clinical benefits [31–33]. Hu et al. [31] reported that SLCO1B1 expression is significantly downregulated in HCC, which is consistent with our findings. In addition, \textit{CDCA7}, as a target gene of hsa-miR-29b-1-5p, is overexpressed in several malignancies [34, 35]. \textit{Inc-EPC1}-4 overexpression induces \textit{miR-29b}-1-5p expression, which provides a potential mechanism for \textit{CDCA7} overexpression and might also explain, in part, the antitumor effects of \textit{inc-EPC1}-4.

Our results also demonstrated that \textit{inc-FAM72D}-3 siRNA-1 induces hsa-miR-5787 expression, while pcDNA3.1-\textit{inc-FAM72D}-3 inhibits hsa-miR-5787

| Table 2. Characteristics of the patients. |
|-----------------------------------------|
| Group | Variable | No. | Group | Variable | No. |
| Healthy (n=45) | Age, years | 29.608 | Cirrhosis (n = 45) | Age, years | 51.496 |
| | mean | 29.608 | | mean | 51.496 |
| | SD | 11.331 | | SD | 10.339 |
| Male | 26 | 34 | Male | 36 |
| Female | 19 | 11 | Female | 9 |
| Serum AFP | <20 ng/ml | 45 | Serum AFP | <20 ng/ml | 33 |
| | ≥20 ng/ml | 0 | | =20–400 ng/ml | 10 |
| | >400 ng/ml | 2 | | >400 ng/ml | 17 |
| Hepatitis (n=45) | Age, years | 41.143 | Liver cancer (n = 45) | Age, years | 52.333 |
| | mean | 41.143 | | mean | 52.333 |
| | SD | 13.155 | | SD | 11.909 |
| Male | 38 | 36 | Male | 9 |
| Female | 7 | 16 | Female | 9 |
| Serum AFP | <20 ng/ml | 20 | Serum AFP | <20 ng/ml | 16 |
| | =20–400 ng/ml | 19 | | =20–400 ng/ml | 12 |
| | >400 ng/ml | 6 | | >400 ng/ml | 17 |
Figure 5. Clinical analysis of AUC of (A) Inc-FAM72D-3, (B) Inc-EPC1-4, (C) Inc-ZEB2-19, and (D) Inc-GPR89B-15 in the control group compared to hepatitis, cirrhosis, and HCC groups. N VS H, normal versus hepatitis; N VS C, normal versus cirrhosis; N VS L, normal versus HCC; AUC, area under the curve; ROC, receiver operating characteristic; HCC, hepatocellular carcinoma.
Table 3. Correlation between expression level of the differentially expressed lncRNAs and clinical characteristics.

| Variable       | No. of case | Inc-FAM72D-3 | Inc-EPC1-4 | Inc-ZEB2-19 | Inc-GPR89B-15 |
|----------------|-------------|--------------|------------|-------------|---------------|
| Age (year)     |             | MEAN         | R          | P           | MEAN          | R          | P           | MEAN          | R          | P           |
| <35            | 57          | 2.847±0.185  | 0.468      | 0           | 21.842±3.410 | 0.165      | 0.02        | 1.68±0.217   | 0.77±0.057  | 0.263       | 0.372±0.374  | 0.266       | 0           |
| ≥35            | 123         | 12.075±1.076 | 42.430±5.82| 0           | 0.02         | 0.165      | 0.02        | 1.68±0.217   | 0.77±0.057  | 0.263       | 0.372±0.374  | 0.266       | 0           |
| Gender         |             |              |            |             |              |            |             |              |              |             |              |             |             |
| Male           | 134         | 19.114±1.898 | -0.493     | 0           | 40.992±6.441 | -0.05      | 0.649       | 0.970±0.131  | 0.044       | 0.414       | 2.752±0.046  | 0.046       | 0.388       |
| Female         | 46          | 4.099±0.307  | 63.036±0.20| 0.16        | 0.003        | -0.037     | 0.493       | 0.118±0.027  | 0.027       |              |              |             |             |
| AFP            |             |              |            |             |              |            |             |              |              |             |              |             |             |
| <20 ng/ml      | 114         | -0.069       | 0.197      | 0.16        | 0.003        | -0.037     | 0.493       | 0.118±0.027  | 0.027       |              |              |             |             |
| ≥20–400 ng/ml  | 42          |              |            |             |              |            |             |              |              |              |              |             |             |
| >400 ng/ml     | 24          |              |            |             |              |            |             |              |              |              |              |             |             |

Abbreviations: AFP, alpha fetoprotein; Inc-FAM72D-3, long non-coding RNA FAM72D-3; Inc-EPC1-4, long non-coding RNA ZEB2-19, long non-coding RNA GPR89B-15.

Figure 6. Effect of Inc-FAM72D-3 and Inc-EPC1-4 suppression and overexpression on candidate targets. (A) has-miR-5787 and EIF5 expression when Inc-FAM72D-3 was suppressed or overexpressed in HepG2 and MHCC-LM3 cells. (B) has-miR-29b-1-5p and STAT3 expression when Inc-EPC1-4 was suppressed or overexpressed in HepG2 and MHCC-LM3 cells. (C) has-miR-511-5p and SLCO1B1 expression when Inc-EPC1-4 was suppressed or overexpressed in HepG2 and MHCC-LM3 cells. (D) has-miR-19b-1-5p and CCND1 expression when Inc-EPC1-4 was suppressed or overexpressed in HepG2 and MHCC-LM3 cells. STAT3, signal transducer and activator of transcription 3.
Figure 7. (A) Cell viability and (B) cell apoptosis in cells with Inc-FAM72D-3 suppression or overexpression. (C) Cell viability and (D) cell apoptosis in cells with Inc-EPC1-4 suppression or overexpression.
expression. However, modulation of Inc-FAM72D-3 fails to affect eukaryotic translation initiation factor 5 (EIF5), which is a target of has-miR-5787 [36]. EIF5 not only plays an important role in the initiation of translation of some proteins but also regulates the occurrence of cancer and promotes cell proliferation, senescence, and apoptosis. Therefore, a mechanism that involves alternate has-miR-5787 targets might account for the oncogenic effects of Inc-FAM72D-3 in HCC cells.

In summary, Inc-FAM72D-3 and Inc-EPC1-4 might be used as diagnostic and prognostic biomarkers for HCC. Future studies that characterize the expression of additional candidate targets of these lncRNAs might help us better define their mechanisms, which might ultimately lead to the development of new diagnostic and therapeutic tools for HCC.

MATERIALS AND METHODS

Exosome purification from serum

Whole blood was collected from 45 healthy volunteers (controls), 45 hepatitis patients, 45 cirrhosis patients, and 45 HCC patients. Serum was isolated from the whole blood and ultracentrifuged using a Beckman L8 ultracentrifuge (GMl, Ramsey, MN, USA) at 100,000×g for 20 h at 10°C. The supernatants were discarded, and pellets containing exosomes were resuspended in phosphate buffer solution (PBS). The size of the exosomes was validated by using nanoparticle tracking analysis (NTA; Particle Metrix, Germany), and the content of membrane proteins, such as CD63, CD9, and TSG101, was verified using western blotting.

Western blotting

Exosomes, HepG2 cells, and MHCC-LM3 cells were lysed in 1% sodium dodecyl sulfate (SDS) lysis buffer. Protein concentrations were evaluated using the bicinchoninic acid (BCA) protein assay kit (Beyotime, Shanghai, China). Proteins were subjected to 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto nitrocellulose membranes. The nitrocellulose membranes were blocked with 5% nonfat milk in PBS for 1 h at room temperature and incubated overnight at 4°C with primary antibodies anti-CD63 (ab134045; Abcam, UK), anti-TSG101 (ab125011; Abcam), anti-CD9 (ab92726; Abcam), and anti-calnexin (ab22595; Abcam). After several washes, the nitrocellulose membranes were incubated in a blocking buffer with a secondary antibody coupled to horseradish peroxidase (HRP) for 2 h at room temperature. The complexes were detected by electrochemiluminescence (ECL) (Amersham Biosciences/GE Healthcare, Velizy, France).

Cell culture

HCC cell lines (HepG2, Hep3B, SNU-423, and PLC/PRF/5) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The human normal liver L02 cell line and Huh-7, MHCC-LM3, and MHCC97-H cells were obtained from CELLCOOK (Guzhou, China) and cultured with 5% CO2 at 37°C. The cells were maintained in high-glucose Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and passaged every 3 days.

LncRNA suppression and overexpression

Full-length lncRNAs were amplified by polymerase chain reaction (PCR) using Thermo Scientific Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific), and corresponding complementary DNAs (cDNAs) were subcloned into the NheI and KpnI sites of pcDNA3.1(+) (GenePharma, China) according to the manufacturer’s instructions. The vectors constructed were verified by Sanger sequencing. Small interfering RNAs (siRNAs) for candidate lncRNAs were designed and synthesized. The vectors and siRNAs were transfected into cell lines using lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. The expression level of lncRNAs and their targeted miRNAs and messenger RNAs (mRNAs) were determined by real-time quantitative PCR (qPCR) (Supplementary Table 1).

MTS assay

Cells were seeded at a density of 1 × 105/mL into 96-well plates (100 μL/well), treated with overexpression vectors or siRNAs, and examined after 24, 48, and 72 h. A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) mixture (Promega Corporation, Madison, WI, USA) was added for 3 h, and the optical density of the cells was detected at a frequency of 490 nm.

Cell apoptosis assay

Cells were resuspended in 1× binding buffer, and 5 μL of fluorochrome-conjugated annexin V and 5 μL of 7-aminoactinomycin D (7-AAD) staining solution (Thermo Fisher Scientific) were added. The cells were assessed using a fluorescence-activated cell sorting
Calibur flow cytometer, and the percentage of the apoptotic cells was measured.

**RNA-seq**

Total RNA was purified from exosomes from the isolated serum from 45 healthy volunteers (controls), 45 hepatitis patients, 45 cirrhosis patients, and 45 HCC patients using the RNeasy Mini Kit (QIAGEN, Germany). RNA integrity was evaluated on the basis of the RNA integrity number (RIN) using Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). RNA was further purified using the RNA Clean XP Kit (Beckman Coulter, Brea, CA, USA), and the DNA residue was removed using the RNase-free DNase Set (QIAGEN). RNA quality and concentration were determined using NanoDrop 2000 (Thermo Fisher Scientific). Ribosomal RNA (rRNA) was removed using the NEBNext rRNA Depletion kit (New England Biolabs, Ipswich, MA, USA). Then, 1 μg of total RNA was used for library preparation using the VAHTSTM mRNA-seq v2 library Prep Kit (Vazyme, Nanjing, China) according to the manufacturer’s instructions. RNA was fragmented and then double-stranded cDNA was synthesized. End-polishing was performed, and the cDNA fragments were ligated with adapters and then subjected to universal PCR amplification in order to obtain a sufficient library for sequencing. The library quality was assessed using Agilent Bioanalyzer 2100. RNA-seq was performed using Illumina Hiseq 4000 (Illumina, San Diego, CA, USA). The data were assembled and annotated with corresponding symbols for transcripts. Differentially expressed lncRNAs were screened using R software (q < 0.05 and fold change > 2.0).

**Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis**

The Database for Annotation, Visualization and Integrated Discovery was used to annotate the potential functions of various signaling pathways for differentially expressed lncRNAs. The functional annotations of parental genes were predicted by GO functional annotation. Scatter plots were used to visualize GO analysis results. KEGG pathway annotation was used to identify relevant pathways of differentially expressed lncRNAs.

**Construction of an lncRNA-miRNA-mRNA network**

We predicted miRNA binding to lncRNA using miRanda software. By inputting miRNA and lncRNA sequences, we predicted the miRNA that lncRNA might combine with and filtered out the miRNA that was differentially expressed in RNA-seq. miRNA target genes were downloaded in miRTarbase, while an lncRNA-miRNA-mRNA regulatory network was constructed using Cytoscape ver. 3.5.1.

**qPCR**

Total RNA was extracted from exosomes and gene expression verified by PCR. cDNA was synthesized from total RNA using M-MLV Reverse Transcriptase (Promega Corporation) according to the manufacturer’s instructions. PCR was performed using the GoTaq qPCR Master Mix (Promega Corporation). PCR amplification was performed using the ABI 7500 system (Applied Biosystems, Foster City, CA, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control.

**Statistical analysis**

Statistical analysis was performed using SPSS Statistics 19 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism (GraphPad Software, CA, USA). Comparisons were performed using independent t-tests, one-way analysis of variance (ANOVA), and two-way ANOVA when data corresponded to a normal distribution. P < 0.05 was considered statistically significant.

**Ethics statement**

This study was approved by the ethics committee of Third Affiliated Hospital of Sun Yat-sen University. The patients provided informed written consent.

**AUTHOR CONTRIBUTIONS**

Conceptualization and Methodology: Qi Zhang, Meihai Deng, and Zhicheng Yao; Validation: Changchang Jia, Yan Tai, and Hao Liang. Formal analysis: Qi Zhang, Zhicheng Yao, and Yan Tai. Investigation: Qi Zhang, Zhicheng Yao, Yan Tai, and Zhaozhong Zhong. Writing-original draft: Qi Zhang and Zhicheng Yao.

**CONFLICTS OF INTEREST**

These authors declare no conflicts of interest.

**FUNDING**

The present study was supported by the National Natural Science Foundation of China (grant no. 81870128), the Science and Technology Planning Project of Guangdong (2014A020212185), the Natural Science Foundation of Guangdong Province (2018A030313641), Young teacher cultivation project of Sun Yat-sen university (19ykpy34).
REFERENCES

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015; 385:117–71. https://doi.org/10.1016/S0140-6736(14)61682-2 PMID:25530442

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7–30. PMID:28055103

3. Kumar N, Choudhary NS, Saraf N, Saigal S. Hepatocellular carcinoma presenting as dyspnea at rest due to innumerable lung metastasis. J Clin Exp Hepatol. 2016; 6:319–20. https://doi.org/10.1016/j.jceh.2016.05.005 PMID:28003722

4. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006; 12:1175–81. https://doi.org/10.3748/wjg.v12.i8.1175 PMID:16534867

5. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013; 500:598–602. https://doi.org/10.1038/nature12451 PMID:23945587

6. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015; 21:1185–96. https://doi.org/10.1038/nm.3891 PMID:26540387

7. Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, Huang Y, Luo J, Liu X, et al. Mesenchymal stem cells promote hepatocarcinogenesis via IncRNA-MUF interaction with ANXA2 and miR-34a. Cancer Res. 2017; 77:6704–16. https://doi.org/10.1158/0008-5472.CAN-17-1915 PMID:28947421

8. Yin J, Luo W, Zeng X, Zeng L, Li Z, Deng X, Tan X, Hu W. UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer. Am J Cancer Res. 2017; 7:462–72. PMID:28401004

9. Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014; 65:1140–51. https://doi.org/10.1016/j.eururo.2013.12.003

10. Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC. The long non-coding RNA Inc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res. 2015; 5:2799–807. PMID:26609485

11. Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao X, Zhu W, Zhang X, Cheng Y, Ou K, Chen Q, Hu S. Circulating IncRNAs associated with occurrence of colorectal cancer progression. Am J Cancer Res. 2015; 5:2258–65. PMID:26328256

12. Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y, Liang W, Hu C, Liu Y, Li J, Wang N, Wei B, Chen L. Genome-wide IncRNA microarray profiling identifies novel circulating IncRNAs for detection of gastric cancer. Theranostics. 2017; 7:213–27. https://doi.org/10.1016/j.eururo.2013.12.003 PMID:28042329

13. Deng L, Yang SB, Xu FF, Zhang JH. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as a let-7 sponge. J Exp Clin Cancer Res. 2015; 34:18. https://doi.org/10.1186/s13046-015-0136-7 PMID:25884472

14. Jing W, Gao S, Zhu M, Luo P, Jing X, Chai H, Tu J. Potential diagnostic value of IncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep. 2016; 37:1085–92. https://doi.org/10.1389/or.2016.4859 PMID:27278245

15. Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, Tran EJ, Merle P, Andrisani O. RNA helicase DEAD box protein 5 regulates polycomb repressive complex 2/hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Hepatology. 2016; 64:1033–44. PMID:27338022

16. Chen F, Bai G, Li Y, Feng Y, Wang L. A positive feedback loop of long noncoding RNA CCAT2 and FOXM1 promotes hepatocellular carcinoma growth. Am J Cancer Res. 2017; 7:1423–34. PMID:28744394

17. Gong J, Qi X, Zhang Y, Yu Y, Lin X, Li H, Hu Y. Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression. Biomol Pharmacother. 2017; 34:16–27. https://doi.org/10.1016/j.biomai.2017.06.004 PMID:28622593

18. Hou Z, Xu X, Fu X, Tao S, Zhou J, Liu S, Tan D. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2017; 36:1085–92. https://doi.org/10.1186/s13046-015-0136-7 PMID:25884472
19. Xu LC, Chen QN, Liu XQ, Wang XM, Chang QM, Pan Q, Wang L, Wang YL. Erratum: up-regulation of LINC00161 correlates with tumor migration and invasion and poor prognosis of patients with hepatocellular carcinoma. Oncotarget. 2019; 10:1474. https://doi.org/10.18632/oncotarget.26712 PMID: 30891158

20. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized function. J Proteomics. 2010; 73:1907–20. https://doi.org/10.1016/j.jprot.2010.06.006 PMID: 20601276

21. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010; 73:1907–20. https://doi.org/10.1016/j.jspromics.2010.06.006 PMID: 20601276

22. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinday Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Maehara Y, Mimori K. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015; 112:532–38. https://doi.org/10.1038/bjc.2014.621 PMID: 25584845

23. Moris D, Beal EW, Chakidis J, Burkhart RA, Schmidt C, Dillhoff M, Zhang X, Theocharis S, Pawlik TM. Role of exosomes in treatment of hepatocellular carcinoma. Surg Oncol. 2017; 26:219–28. https://doi.org/10.1016/j.suronc.2017.04.005 PMID: 28807240

24. Zhang Z, Li X, Sun W, Yue S, Yang J, Li J, Ma B, Wang J, Yang X, Pu M, Ruan B, Zhao G, Huang Q, et al. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. Cancer Lett. 2017; 397:33–42. https://doi.org/10.1016/j.canlet.2017.03.004 PMID: 28288874

25. Zhang C, Chi YL, Wang PY, Wang YQ, Zhang YX, DENG J, LV CJ, Xie SY. miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS One. 2012; 7:e46090. https://doi.org/10.1371/journal.pone.0046090 PMID: 23071539

26. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through akt activation: evidence for akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003; 38:756–68. PMID: 12939602

27. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 2005; 103:307–12. PMID: 15593087

28. Schmitz KJ, Wohlschlager J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinanni VR, Schmid KW, Baba HA. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008; 48:83–90. https://doi.org/10.1016/j.jhep.2007.08.018 PMID: 17998146

29. Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Ariti S, Inazawa J, Okanoue T. Activation of b-myb by E2F1 in hepatocellular carcinoma. Hepatol Res. 2008; 38:886–95. PMID: 18624722

30. Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W, Li X. MicroRNA-29B (mir-29b) regulates the warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget. 2015; 6:40799–814. https://doi.org/10.18632/oncotarget.5695 PMID: 26512921

31. Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. J Pharmacol Exp Ther. 2019; 368:363–81. https://doi.org/10.1124/jpet.118.255018 PMID: 30578287

32. Sekine S, Ogawa R, Ojima H, Kanai Y. Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci. 2011; 102:1742–47. PMID: 21615622

33. Herrera E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013; 58:1065–73. PMID: 23532667

34. Martín-Cortáz C, Chido Y, Jiménez RP, Bernabé M, Cayuela ML, Iglesias T, Campanero MR. CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion. Haematologica. 2020; 105:730–40. https://doi.org/10.3324/haematol.2018.215459 PMID: 31221787
35. Ye L, Li F, Song Y, Yu D, Xiong Z, Li Y, Shi T, Yuan Z, Lin C, Wu X, Ren L, Li X, Song L. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer. Int J Cancer. 2018; 143:2602–13. https://doi.org/10.1002/ijc.31766 PMID:30151890

36. Yoo H, Yoo JK, Lee J, Lee DR, Ko JJ, Oh SH, Choo YK, Kim JK. The hsa-miR-5787 represses cellular growth by targeting eukaryotic translation initiation factor 5 (eIF5) in fibroblasts. Biochem Biophys Res Commun. 2011; 415:567–72. https://doi.org/10.1016/j.bbrc.2011.10.103 PMID:22062548
Supplementary Figure 1. Validation of exosome purification. (A) Size distribution of exosomes in control, hepatitis, cirrhosis, and HCC groups. (B) Western blot analysis of exosome-specific proteins (CD63, TSG101, and CD9) in control, hepatitis, cirrhosis, and HCC groups and calnexin protein analysis in control, hepatitis, cirrhosis, and HCC groups and HepG2 and MHCC-LM3 cells. HCC, hepatocellular carcinoma.
Supplementary Figure 2. Relative Inc-FAM72D-3, Inc-EPC1-4, Inc-ZEB2-19, and Inc-GPR89B-15 expression in different cell lines determined by real-time qPCR. qPCR, quantitative polymerase chain reaction.
Supplementary Figure 3. Suppression and overexpression of Inc-FAM72D-3 and Inc-EPC1-4 in different cells. (A) Inc-FAM72D-3 expression in different cells treated with siRNA and Inc-FAM72D-3 overexpression vector. (B) Inc-EPC1-4 expression in different cells treated with siRNA and Inc-EPC1-4 overexpression vector. siRNA, small interfering RNA.
### Supplementary Table 1. LncRNA and miRNA primer sequence for quantitative real time (qPCR).

| LncRNA       | Noncode transcript ID | Primer sequence                  |
|--------------|-----------------------|---------------------------------|
| Inc-RUFY4-1  | NONHSAT076871.2-F     | ACAGGTTAAGGGAGGCGGAA            |
|              | NONHSAT076871.2-R     | CAGAAATCCACAGCCAGCA             |
| Inc-MFSD1-2  | NONHSAT092952.2-F     | AATGGATTGGGAGGTTGAAGG           |
|              | NONHSAT092952.2-R     | CCGACCTCACTAGAGCAAAA            |
| Inc-RDH8-2   | NONHSAT061016.2-F1    | CCTGCAAATGGGAACGGGGA            |
|              | NONHSAT061016.2-R1    | GCGGTAAGAGGAGGATGAGG            |
| Inc-GPR89B-15:1 | Inc-GPR8913-151-F   | GGTTGCTAAGTGTCAGAGA             |
|              | Inc-GPR8913-151-R     | GCTATAATCTATGGGACGACT            |
| Inc-FAM72D-3 | NONHSAT149711.1-F     | TGGCAGAAGTTGAACTAAG             |
|              | NONHSAT149711.1-R     | AGTGAGATGGGGTGACTG              |
| Inc-NBEA-8   | NONHSAT165530.1-F2    | TGGAGTTCTCTGTATCCCTACC          |
|              | NONHSAT165530.1-R2    | CCAGGAAAGATGTCAAAGGAAGGAAGAAG  |
| Inc-ZEB2-19  | NONHSAT074841.2-F     | GGCGAGCTTGGAGGACTG              |
|              | NONHSAT074841.2-R     | CCTCAGTTGTAGGGCGACGT             |
| Inc-EPC1-4   | NONHSAT156862.1-F1    | AAGTGTGCGAGAAGAAGAGC            |
|              | NONHSAT156862.1-R1    | TCAGTGCCGAGATTGTACG             |
| Inc-FAM21A-2 | NONHSAT155490.1-F     | ATTGGCACTGGCTGGGATAC            |
|              | NONHSAT155490.1-R     | GCAGTGAGAAGAACCTATGCCT          |

| miRNA        | Primer sequence                  |
|--------------|---------------------------------|
| hsa-miR-5787 | GGCGAAATGGCAAGGTTGAGGG          |
|              | GGGAGGACGAGGAGGTTGAGGG          |
| hsa-miR-5787-RT | GCTGATCCAGTGGAGGTTGAGGG         |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-29b-1-5p-F | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-29b-1-5p-RT | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-19b-1-5p-F | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-19b-1-5p-RT | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-511-5p-RT | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| hsa-miR-511-5p-F | GCTGTATCCAGTGGAGGTTGAGGG        |
|              | ACTCGCTCCAGGAGGTTGAGGG          |
| H-SLCO1B1-1  | ACTGATTCTCTGATGGGTTG          |
| H-SLCO1B1-1-R | ACTGATTCTCTGATGGGTTG          |
| H-ELF5-F     | GCTGATCCAGTGGAGGTTGAGGG        |
| H-ELF5-R     | GCTGATCCAGTGGAGGTTGAGGG        |
| H-STAT3-1    | ACTGATTCTCTGATGGGTTG          |
| H-STAT3-1-R  | ACTGATTCTCTGATGGGTTG          |
| H-CCND1-1    | ACTGATTCTCTGATGGGTTG          |
| H-CCND1-1-R  | ACTGATTCTCTGATGGGTTG          |
| Inc-FAM72D-3 siRNA-1 | GAGAAATGGAGTGAGGCTTTT          |
| Inc-FAM72D-3 siRNA-2 | GGGACTGGAGTGAAGATTTT          |
| Inc-FAM72D-3 siRNA-3 | GCGATATCCATTATGTCCA            |
| Inc-EPC1-4 siRNA-1 | GACATTAATGGGAAGCTCTGT          |
| Inc-EPC1-4 siRNA-2 | GACATTAATGGGAAGCTCTGT          |
| Inc-EPC1-4 siRNA-3 | GACATTAATGGGAAGCTCTGT          |
Please browse Full Text version to see the data of Supplementary Tables 2 to 4.

**Supplementary Table 2.** The differentially expressed IncRNA in Normal group vs. Hepatitis group.

**Supplementary Table 3.** The differentially expressed IncRNA in Normal group vs. Cirrhosis group.

**Supplementary Table 4.** The differentially expressed IncRNA in Normal group vs. Liver cancer group.